Treatment of Oral Warts in HIV+ Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

September 30, 2009

Study Completion Date

October 31, 2009

Conditions
PapillomatosisHIV Infections
Interventions
DRUG

Interferon-alpha

500 IU interferon-alpha lozenges taken 3 times per day for 24 weeks

OTHER

placebo

200 mg lozenges containing anhydrous crystalline maltose taken three times per day for 24 weeks

Trial Locations (12)

10010

New York University College of Dentistry, New York

19104

University of Pennsylvania School of Dental Medicine, Philadelphia

21201

University of Maryland Baltimore Dental School, Baltimore

60612

University of Illinois at Chicago, College of Dentistry, Chicago

75246

Baylor College of Dentistry, Dallas

94143

University of California, School of Dentistry, San Francisco

33328-2018

Nova Southeastern University College of Dental Medicine, Fort Lauderdale

30912-1241

Medical College of Georgia School of Dentistry, Augusta

40536-0297

University of Kentucky College of Dentistry, Lexington

02115

Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, Boston

07108

UMDNJ - New Jersey Dental School, Newark

78229-3900

University of Texas Health Science Center at San Antonio, San Antonio

All Listed Sponsors
lead

Ainos, Inc. (f/k/a Amarillo Biosciences Inc.

INDUSTRY

NCT00454181 - Treatment of Oral Warts in HIV+ Patients | Biotech Hunter | Biotech Hunter